Corticosteroids for sepsis: registry versus Cochrane systematic review! by Annane, Djillali
A recent report from the PROGRESS registry warned 
readers of potential danger associated with the use of 
corticosteroids in patients with severe sepsis or septic 
shock [1]. In this retrospective analysis, 3,051 out of 8,968 
(34%) patients received treatment with low dose cortico-
steroids. Corticosteroid-treated patients were older, had 
more co-morbidities and greater severity of illness than 
patients who did not receive corticosteroids. Subse  quently, 
there were more deaths among corticosteroid-treated 
patients even after controlling for various confounders.
What is the current evidence on the benefi  t to 
risk ratio of corticosteroids in patients with septic 
shock?
A recent Cochrane systematic review of corticosteroid 
treatment for severe sepsis and septic shock found 17 
randomized controlled trials (n = 2,138) and 3 quasi 
randomized trials (n = 246) [2]. Computing data from the 
17 randomized trials yielded a signiﬁ  cant survival beneﬁ  t 
from corticosteroids with a risk ratio (RR) of 0.84 (95% 
conﬁ  dence interval (CI), 0.71 to 1.00; P = 0.05). Th  ere  was 
a strong heterogeneity across the studies (I2  =  53% by 
random-eﬀ  ects model), which was mainly explained by 
diﬀ   erences in treatment strategies. Indeed, the meta-
regression using dose and treatment duration showed 
that survival beneﬁ  t was strongly dependent on the dose 
of cortico  steroids (P = 0.02) - the lower the better - and 
the dura  tion of treatment (P  =  0.01) - the longer the 
better. Th  en, subgroup analysis based on 12 trials 
(n = 1,228) of prolonged treatment (5 days or more at full 
dose) with low dose (lower than 300 mg per day of 
hydrocortisone or equivalent) corticosteroids found that 
28-day mortality for treated versus control patients was 
236 out of 629 (37.5%) versus 264 out of 599 (44.1%) (RR, 
0.84; 95% CI, 0.72 to 0.97; P = 0.02) without heterogeneity 
across the studies (I2 = 15%). In this systematic review, 
there was no evidence for increased risk of gastro-
intestinal bleeding (n = 1,594; RR, 1.12; 95% CI, 0.81 to 
1.53; P = 0.50), superinfection (n = 1,917; RR, 1.01; 95% 
CI, 0.82 to 1.25; P = 0.92) or neuromuscular weakness 
(n = 811; RR, 0.63; 95% CI, 0.12 to 3.35; P = 0.58), while 
corticosteroids were associated with hyperglycaemia 
(n = 1,434; RR, 1.16; 95% CI, 1.07 to 1.25; P < 0.001) and 
hypernatraemia (n = 805; RR, 1.61; 95% CI, 1.26 to 2.06; 
P < 0.001). Of note, normalizing blood glucose levels in 
corticosteroid-treated septic shock did not aﬀ  ect 
mortality [3]. Th  us, it is unlikely that corticosteroids 
increased the risk of death in severe sepsis or septic 
shock as suggested by Beale and colleagues [1]. Never-
theless, given the opposite ﬁ   ndings of the two largest 
trials of low dose corticosteroids [4,5], which might be 
explained by diﬀ   erences in severity of illness, current 
recommendations suggest that low dose corticosteroids 
should be considered only in patients who are poorly 
responsive to ﬂ  uids and vaso  pressors [6].
Why should we be cautious in drawing conclusions 
from the PROGRESS registry?
As highlighted by the authors, this was a retrospective 
analysis of data from a registry that was set up to assess 
the routine use of activated protein C and not to 
investigate the beneﬁ  t to risk ratio of corticosteroids [1]. 
Th   en, there is uncertainty on the modalities of 
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time of treatment initiation, the exact dose and the 
duration of treatment. Of note, the recent Cochrane 
systematic review showed that the beneﬁ  t to risk ratio of 
corticosteroids was favourably inﬂ   uenced by early 
treatment, lower doses and longer duration [2]. As the 
use of corticosteroids was not controlled in patients 
included in the PROGRESS registry, any conclusion 
about treatment beneﬁ  t or harm is severely ﬂ  awed.
What should we really worry about?
Th  e most valuable information from the study of Beale 
and colleagues [1] is the apparently high proportion 
(14%) of vasopressor-free patients who received treat-
ment with corticosteroids. Th  ere is some evidence to 
support the use of corticosteroids in target populations 
regardless of the presence of shock, including patients 
with bacterial meningitis, typhoid fever, pneumocystis 
pneumonia, or severe community acquired pneumonia 
[7]. Unfortunately, the study by Beale and colleagues 
includes no information on the type of infections in the 
vasopressor-free patients who were treated with 
corticosteroids. We should worry about the unnecessary 
use of corticosteroids in patients with sepsis and without 
shock only in those with infections other than those cited 
above.
Where are we now?
Th   ere are ongoing trials to conﬁ  rm the beneﬁ  t of cortico-
steroids in septic shock (APROCCHS, NCT00625209) or 
in severe sepsis without shock (HYPRESS, NCT00670254). 
While waiting for the results of these trials, the current 
evidence supports the use of low dose corticosteroids 
(200 mg of hydrocortisone or equivalent per day for at 
least 5 days) in patients with septic shock who require 
0.25 μg/kg/minute or more of norepinephrine (or equiva-
lent) and in adults with bacterial meningitis or severe 
community acquired pneumonia.
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